CVT-ISR First in Human Trial for Coronary In-Stent Restenosis

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

51 participants

Study Classification

INTERVENTIONAL

Study Start Date

2021-10-20

Study Completion Date

2025-05-08

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The goal of this first in human study is to assess the safety and inhibition of restenosis of the CVT Everolimus-coated PTCA Catheter in the treatment of subjects presenting in-stent restenotic lesions in native coronary arteries.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Absorb Bioresorbable Scaffold vs. Drug Coated Balloon for Treatment Of In-Stent-Restenosis

NCT03529006

In-stent Restenosis

UNKNOWN NA

Restenosis Intrastent: Treatment of Bioresorbable Vascular Scaffolds Restenosis

NCT03167424

Coronary In-stnent Restenosis

UNKNOWN

Treatment of Coronary In-Stent Restenosis

NCT01735825

Restenosis

COMPLETED NA

A Safety and Efficacy Study of Dissolve™ in Treatment of Coronary In-stent Restenosis

NCT03373695

Coronary In-stent Restenosis

COMPLETED NA

Drug-Coated Balloon Coronary Angioplasty Versus Stenting for Treatment of Disease Adjacent to a Chronic Total Occlusion.

NCT04881812

Chronic Total Occlusion of Coronary Artery

UNKNOWN NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The CVT-ISR Trial is a prospective, multi-center, open, single arm study enrolling subjects with visually estimated nominal vessel diameter ≥2.0 mm and ≤3.5mm and lesion length ≤24 mm receiving up to two (2) CVT Everolimus CVT EVE-PTCA Catheters.

An angiographic follow up, in combination with either Intravascular Ultrasound (IVUS) or Optical Coherence Tomography (OCT), follow-up, will be carried out in a subset of 25 patients at 180 days following the index procedure.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

In-stent Restenosis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Drug eluting balloon

Treatment of a single in-stent restenosis coronary artery lesion with drug eluting balloon

Group Type EXPERIMENTAL

Drug Eluting Balloon

Intervention Type DEVICE

PCI of in-stent restenosis

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Drug Eluting Balloon

PCI of in-stent restenosis

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Subject must be at least 18 years of age.
2. Subject or his/her legally authorized representative provides written informed consent prior to any clinical investigation related procedure, as approved by the appropriate Ethics Committee of the respective clinical site.
3. Subject must agree to undergo all clinical investigation plan-required follow-up visits, angiograms, IVUS/OCT and examinations.

1. Target lesion must be located within a stent (bare metal or drug eluting) placed in a native epicardial coronary vessel with visually estimated nominal vessel diameter of ≥2.0mm and ≤3.5mm.
2. Target lesion must measure ≤24 mm in length by visual estimation.
3. The target lesion must be with a visually estimated stenosis of ≥50% and \< 100% with a TIMI flow of ≥1.
4. Non-clinical investigation, percutaneous intervention for lesions in a non-target vessel is allowed if done ≥90 days prior to or planned to be done 6 months after the index procedure.
5. Non-clinical investigation, percutaneous intervention for lesions in the target vessel is allowed if planned to be done 6 months after the index procedure.

Exclusion Criteria

1. Subject with known diagnosis of acute myocardial infarction (AMI) within 30 days preceding the index procedure and CK-MB or troponin have not returned within normal limits at the time of procedure.
2. The subject is currently experiencing clinical symptoms consistent with AMI.
3. Subject has current unstable arrhythmia.
4. Subject has a known left ventricular ejection fraction (LVEF) \<25%.
5. Subject has a known hypersensitivity or contraindication to aspirin, both heparin and bivalirudin, both clopidogrel and ticlopidine and structurally related compounds, everolimus, or contrast sensitivity that cannot be adequately pre-medicated.
6. Subject has known renal insufficiency (e.g., serum creatinine \> 2.5 mg/dL, (i.e. 221 µmol/L) within 7 days prior to index procedure or creatinine clearance \<30mL/min or subject is on dialysis.
7. Subject has a history of bleeding diathesis or coagulopathy or will refuse blood transfusions.
8. Subject has had a cerebrovascular accident (CVA) or transient ischemic neurological attack (TIA) within the past six months.
9. Subject has other medical illness (e.g., cancer or congestive heart failure) or known history of substance abuse (alcohol, cocaine, heroin etc.) that may cause non-compliance with the clinical investigation plan, confound the data interpretation or is associated with a limited life expectancy (i.e., less than one year).
10. Subject is already participating in another clinical investigation that has not yet reached its primary endpoint.
11. Subject is not, in the opinion of the investigator, an acceptable candidate to participate in the study.
12. In-stent lesions for stent are located within an arterial or saphenous vein graft or stent used to treat a previous ISR.
13. The target vessel contains visible thrombus.
14. Pregnant or lactating females.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No